Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles

NCT03066011 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.

NCT NCT03066011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03066011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles
Lead sponsor
Astellas Pharma Global Development, Inc.
Phase
Observational
Overall status
Completed
Start date
March 16, 2017
Completion date
April 24, 2020
Enrollment
2,015 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

invasive fungal infection